Thursday, March 23, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

NEOMED Creates New Biologics and Vaccine Centre of Excellence

by Global Biodefense Staff
February 6, 2015
Ebola Vaccine Safety Trials

NEOMED, a Canadian-based not-for-profit organization whose mission is to foster the development of promising therapeutic approaches emerging from academia and biotechnology companies, this week announced the launch of the Biologics and Vaccine Centre of Excellence in Laval, Quebec under a proposed partnership with GSK.

This Centre will be unique in Canada and GSK has committed $47 million towards its establishment.

“We are extremely happy to announce the creation of NEOMED’s biologics and vaccines division, a Centre of Excellence that will build on the scientific heritage of GSK and the successful business model of the NEOMED Institute research hub in Technoparc Montréal’s Saint-Laurent Campus,” said NEOMED President and CEO Max Fehlmann. “This Centre will allow Quebec to generate significant economic benefits and offer many companies in Quebec, Canada, and abroad access to state-of-the-art facilities and to an expertise of exceptional quality.”

The GSK proposed partnership will ensure that the expertise remains in Montreal. It will allow both the preservation of 50 jobs and the eventual creation of new positions. It will also increase opportunities for new discoveries to make the necessary step toward commercialization.

The new NEOMED biologics and vaccines division will include creation of a specialized contract research organization (CRO) that will market its biology and clinical immunology services to the business community and to GSK; and the creation of an exclusive partnership between GSK and NEOMED in order to share risks and benefits on existing biologic and vaccine projects.

“We are very pleased to partner with NEOMED to create a unique Biologics and Vaccine Centre of Excellence,” said Paul Lirette, President, GSK Canada Pharmaceuticals. “It enables GSK to look externally and develop collaborative partnerships to optimize R&D, and represents the dawn of a new and promising era for pharmaceutical research in the Montreal region.”

NEOMED is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada.

Tags: Vaccines

Related Posts

Liverpool Synthetic Biology Lab Backed By 2M Award
Policy + Initiatives

Political Interference: White House Launches Framework to Protect Scientific Integrity

January 13, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC